Opinion|Videos|December 15, 2023
Key Takeaways on Recent Data in Breast Cancer from SABCS 2023
Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Behind the FDA Approval of Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
PRV111 Shows Strong Responses in Early Oral Cancer
5